A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States

By afschroeder • October 10, 2025

Cummings AL, Sussell J, Rosettie KL, El Moustaid F, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States. Am J Clin Oncol. 2025 Oct 8. doi: 10.1097/COC.0000000000001248. Epub ahead of print. PMID: 41066159.

Tags: adjuvant treatment, Alectinib, anaplastic lymphoma kinase, Hematology/Oncology, Non-small cell lung cancer, platinum-based chemotherapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

Silverstein JF, Smick A, Tsui E, Alomaja O, Johnson B, Tseng CH, Salani R, Slamon DJ, Chase DM, Konecny GE. Mirvetuximab Soravtansine Exposure and Incidence[...]

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]